{"brief_title": "A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer", "brief_summary": "This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals.", "condition": ["Colorectal Cancer"], "intervention_type": ["Drug", "Drug", "Drug", "Drug", "Drug"], "intervention_name": ["capecitabine [Xeloda]", "Oxaliplatin", "Oxaliplatin", "Leucovorin", "5 FU"], "description": ["1000mg/m2 iv bid on days 1-15 of each 3 week cycle", "As prescribed, in 3 week cycles", "As prescribed, in 2 week cycles", "As prescribed, in 2 week cycles.", "As prescribed, in 2 week cycles"], "arm_group_label": ["1", "1", "2", "2", "2"], "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - colon cancer; - complete tumor resection. Exclusion Criteria: - prior treatment with cytotoxic chemotherapy, radiotherapy, or immunotherapy for the currently treated colon cancer.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Colorectal Neoplasms", "Colonic Neoplasms", "Capecitabine", "Oxaliplatin"], "id": "NCT00069121"}